With mutation-driven therapies and advanced biomarkers shaping the future, AML trials now demand more speed, precision, and operational agility than ever before.
Sheridan, WY, 13...
AI-powered discovery platform EVA™ drives development of a highly selective T-cell engager showing over 90% tumor growth inhibition in pre-clinical studies.
London, 13 November 2025...
Ganaplacide lumefantrine combination delivers cure rates above WHO standards, offering new hope against growing artemisinin resistance.
London, 13 November 2025 – A major step forward...
Robust revenue expansion, higher profitability, strategic acquisitions, and new product launches position Zydus for a strong year ahead.
Sheridan, WY, 13 November 2025 – Zydus...
TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, has officially...
